Myriad to Announce Fiscal Third-Quarter 2017 Financial Results on May 2, 2017
April 18 2017 - 4:05PM
Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will
hold its fiscal third-quarter 2017 sales and earnings conference
call with investors and analysts at 4:30 p.m. ET on Tuesday, May 2,
2017. During the call, Mark C. Capone, president and CEO and
Bryan Riggsbee, CFO, will provide an overview of Myriad’s financial
performance for the fiscal third-quarter and provide a business
update.
To listen to the call, interested parties in the
United States may dial 888-225-2744 or +1 303-223-2690 for
international callers. All callers will be asked to reference
reservation number 21849837. The conference call also will be
available through a live webcast and a slide presentation
pertaining to the earnings call will also be available under the
investor section of our website at www.myriad.com. A replay
of the call will be available two hours after the end of the call
for seven days and may be accessed by dialing 800-633-8284 within
the United States or +1 402-977-9140 for international callers and
entering reservation number 21849837.
About Myriad GeneticsMyriad
Genetics Inc., is a leading personalized medicine company dedicated
to being a trusted advisor transforming patient lives worldwide
with pioneering molecular diagnostics. Myriad discovers and
commercializes molecular diagnostic tests that: determine the risk
of developing disease, accurately diagnose disease, assess the risk
of disease progression, and guide treatment decisions across six
major medical specialties where molecular diagnostics can
significantly improve patient care and lower healthcare
costs. Myriad is focused on three strategic
imperatives: transitioning and expanding its hereditary
cancer testing markets, diversifying its product portfolio through
the introduction of new products and increasing the revenue
contribution from international markets. For more information
on how Myriad is making a difference, please visit the Company's
website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis,
Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk
Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor
BRACAnalysis CDx, myChoice HRD, Vectra, GeneSight, EndoPredict and
Prolaris are trademarks or registered trademarks of Myriad
Genetics, Inc. or its wholly owned subsidiaries in the United
States and foreign countries. MYGN-F, MYGN-G.
Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024